FIG. 3.

Longitudinal in vivo-activated CTL lysis of vaccinia virus-expressed HIV-1 proteins or peptides representing optimal HLA class I-restricted CTL epitopes by subject 115i. Freshly isolated PBMC were incubated with vaccinia virus-infected autologous B-LCL or peptide-pulsed B-LCL at an E/T ratio of 100:1. Background lysis against NYCBH vaccinia virus-infected target cells was <12% at all time points except on day 20 after the start of therapy, when it was 24%. In each case background lysis was subtracted. Background lysis against unpulsed B-LCL targets was always <5%. The targets used were Vac-Gag (a), Vac-RT (b), Vac-Env (c), Vac-Nef (d), SLYNTVATL (HLA A2 restricted) (e), and ERYLKDQQL (HLA B14 restricted) (f).